Patients dependent on oral steroids:
When transfer from oral steroids is initiated the patient must be in a relatively stable condition. A high dose of Pulmicort is given in combination with the previously used oral steroid dose for 10 days. After that, the oral dose should be gradually reduced by e.g. 2.5 mg prednisolone or equivalent per month to the lowest possible level. The oral steroid can often be discontinued entirely.

Treatment control
An incorrect inhalation technique with conventional inhalation sprays is very common. The patients’ inhalation technique should therefore be checked at regular intervals.

There is no experience of treatment of patients with impaired hepatic or renal function. Since budesonide is predominantly eliminated through hepatic metabolism, increased exposure may be expected in patients with severe cirrhosis of the liver.

Instructions for correct use of Pulmicort pMDI
On actuation of Pulmicort pressurised metered dose inhaler, a suspension of the substance is pumped out of the canister at a high velocity. When the patient inhales through the mouthpiece at the same time as releasing a dose, the substance will follow the inspired air into the airways.

Note: It is important to instruct the patient
• To carefully read the instructions for use: “How to use Pulmicort pressurised metered dose inhaler”
• To shake the inhaler thoroughly to mix the contents of the inhaler properly
• To breathe in slowly and deeply through the mouthpiece and to release the dose whilst continuing to breathe in
• To rinse the mouth out with water after inhaling the prescribed dose to minimise the risk of oropharyngeal thrush

For infants and small children and for patients who are unable to coordinate release of the dose and inhalation, an inhalation aid, consisting of a spacer...
together with a mouthpiece, should be used. The dose is deposited in the spacer and the patient inhales through the mouthpiece. For small children a facemask should be used.

**Contraindications**

Hypersensitivity to budesonide or to any of the other ingredients.

**Special warnings and precautions for use**

In order to minimise the risk of Candida infections in the oral cavity and throat, the patient should be instructed to rinse the mouth with water after each dose administration.

Concomitant treatment with ketoconazole, itraconazole or other potent CYP3A4 inhibitors should be avoided. If this is not possible, the interval between the administrations of the drugs should be as long as possible.

Particular care is needed in patients transferring from oral steroids, since they may remain at risk of impaired adrenal function for a considerable time. Patients who have required high dose emergency corticosteroid therapy or prolonged treatment at the highest recommended dose of inhaled corticosteroids, may also be at risk. These patients may exhibit signs and symptoms of adrenal insufficiency when exposed to severe stress. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.

Caution must be observed in treatment of patients who are transferred from systemically acting corticosteroids to Pulmicort and in cases of suspected disturbance of pituitary-adrenocortical function. In these patients there should be a cautious reduction of the dose of systemic steroid, and tests of hypothalamic-pituitary-adrenocortical function should be considered. They may also require the adjunct of systemic steroids in connection with periods of stress, e.g. surgery, trauma, etc.

During the transfer from oral steroid therapy to Pulmicort, patients may experience the return of previous symptoms such as muscle and joint pain. In these cases a temporary increase of the oral steroid dose may sometimes be necessary. If, in isolated cases, fatigue, headache, nausea, vomiting or similar symptoms occur, a generally unsatisfactory effect of the steroid should be suspected.

Replacement of systemic steroid treatment by Pulmicort sometimes reveals allergies, e.g. rhinitis and eczema, that were previously controlled by the systemic treatment.

Regular monitoring of growth is recommended in children and adolescents receiving long-term treatment with corticosteroids, irrespective of the administration form. The benefits of corticosteroid treatment must be placed in relation to possible risks of inhibition of growth.

Patients must be instructed to contact their physician if the effect of the treatment generally diminishes, as repeated inhalations for severe asthma attacks must not delay the initiation of other important therapy. If there is a sudden deterioration the treatment must be supplemented with a short course of oral steroids.

**Interactions**

No clinically relevant interactions with other agents for asthma are known.

Ketoconazole 200 mg once daily increased the plasma concentrations of oral budesonide (3 mg in a single dose) on average six-fold when administered concomitantly. When ketoconazole was administered 12 hours after budesonide, the concentration was increased on average three-fold. Information about this interaction is lacking for inhaled budesonide, but markedly increased plasma levels are also expected in such cases. The combination should be avoided since data to support dose recommendations are lacking. If this is not possible, the time interval between administration of ketoconazole and budesonide should be as long as possible. Other potent inhibitors of CYP3A4, i.e. itraconazole also cause a marked increase in the plasma levels of budesonide.

**Pregnancy and lactation**

**Pregnancy**

Data from approximately 2000 pregnancies have not revealed any increased risk of malformations as a result of treatment with budesonide. Animal studies...
have shown that glucocorticosteroids can induce malformations, but this is judged not to be relevant for humans with the recommended dosage. During pregnancy the aim must be the lowest effective dose of budesonide while taking account of the risk of a worsening of the asthma.

**Lactation**
It is not known whether budesonide passes into breast milk.

**Effects on ability to drive and use machines**
Pulmicort does not affect the ability to drive or use machines.

**Undesirable effects**
Up to 10% of patients treated may be expected to experience adverse reactions of a local nature.

<table>
<thead>
<tr>
<th>Common (&gt;1/100)</th>
<th>Airways:</th>
<th>Candida infection in the oropharynx, irritation in the throat, coughing, hoarseness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare (&lt;1/1000)</td>
<td>General:</td>
<td>Angioedema. Urticaria, rash, dermatitis</td>
</tr>
<tr>
<td></td>
<td>Skin:</td>
<td>Urticaria, rash, dermatitis</td>
</tr>
<tr>
<td></td>
<td>Airways:</td>
<td>Bronchospasm</td>
</tr>
</tbody>
</table>

Occasional cases of nervousness, restlessness, depression and behavioural disturbances have been observed. On account of the risk of Candida infections in the oropharynx the patient must rinse the mouth with water after every dose.

In isolated cases signs or symptoms of systemic glucocorticoid effects may occur, including adrenal hypofunction.

Isolated cases of bruising have occurred.

**Overdose**
Acute overdose with Pulmicort, even in high doses, is not expected to cause any clinical problems. If used chronically in high doses, systemic effects of glucocorticosteroids such as hypercortisolism and adrenal suppression can occur.

**Pharmacodynamic properties**
Budesonide is a glucocorticosteroid with high local anti-inflammatory effect. The precise mechanism of action of glucocorticosteroids in the treatment of asthma is not fully understood. Anti-inflammatory effects such as inhibited release of inflammatory mediators and inhibition of cytokine-mediated immune response are probably important. The activity of budesonide, measured as its affinity for glucocorticosteroid receptors is approx. 15 times higher than that of prednisolone. Budesonide has anti-inflammatory effects shown as reduced bronchial obstruction during both the early and the late phase of an allergic reaction. In hyper-reactive patients budesonide reduces the histamine and metacholine reactivity in the airways.

Studies have shown that the earlier budesonide treatment is initiated after the onset of asthma, the better lung function can be expected.

Studies in healthy volunteers with Pulmicort Turbuhaler have shown dose-related effects on plasma and urinary cortisol. At recommended doses, Pulmicort Turbuhaler, causes significantly less effect on the adrenal function than prednisone 10 mg, as shown by ACTH tests.

In children over the age of 3 years, no systemic effects have been detected with doses up to 400 micrograms per day. In the range 400-800 micrograms per day biochemical signs of a systemic effect may occur. With daily doses in excess of 800 micrograms such signs are common.

Asthma, like inhaled corticosteroids, can delay growth. However, studies in children and adolescents who were treated with budesonide for a long period (up to 11 years) show that the patients reach the expected adult height.

Inhalation therapy with budesonide is effective in preventing exercise-induced asthma.

**Pharmacokinetic properties**

**Absorption**
Inhaled budesonide is rapidly absorbed. The peak plasma concentration is reached within 30 minutes after inhalation. In studies, the average deposition of budesonide in the lungs after inhalation via pressurised spray has been shown to be 10-15% of the metered dose. The systemic bioavailability is approx. 26% of the metered dose.

**Distribution and metabolism**
Plasma protein binding is approx. 90%. The volume of distribution is approx. 3 l/kg. Budesonide undergoes extensive (approx. 90%) first pass metabolism in the liver to metabolites with
low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6b-hydroxybudesonide and 16a-hydroxyprednisolone, is less than 1% of that of budesonide.

**Elimination**

Budesonide is eliminated through metabolism, catalysed primarily by the enzyme CYP3A4. The metabolites are excreted in the urine in unchanged or conjugated form. Only negligible amounts of unchanged budesonide are recovered in the urine. Budesonide has a high systemic clearance (approx. 1.2 l/min), and the plasma half-life after intravenous administration is on average 4 hours. The pharmacokinetics of budesonide is proportional to the dose at relevant dosages.

The pharmacokinetics of budesonide in children and in patients with impaired renal function is unknown. Exposure to budesonide may be increased in patients with hepatic disease.

**List of excipients**

Sorbitan trioleate, trichlorofluoromethane, dichlorotetrafluoroethane, dichlorodifluoromethane.

**Incompatibilities**

Not relevant.

**Shelf-life**

Please refer to expiry date on outer carton.

**Special precautions for storage**

Do not store above 30°C. Store with the valve downwards.

**Pack size**

Please refer to outer carton for pack size.

**Date of revision of the text**

January 2005

**How to use Pulmicort pressurised metered dose inhaler**

Note: In the printed leaflet, clarifying pictures are included in this part

1. Remove the protective cap.
2. Shake thoroughly to mix the contents of the inhaler properly.
3. Close your lips around the mouthpiece.
4. Breathe out calmly through the mouthpiece.

5. Breathe in and release a dose. After starting to breathe in slowly and deeply through your mouth, press the inhaler firmly to release the dose and continue to breathe in.
6. Hold your breath as long as possible, preferably for 10 seconds, and then breathe out.

If a further dose is prescribed, shake the inhaler again and repeat points 2-6.

7. Rinse your mouth out with water after each dosing occasion.

You can check how many dose there are left in the aerosol by placing it in a bowl of water.

**Note:**

It is important that the dose is released at the same time as you breathe in. This allows as much as possible of the dose to penetrate deep down into the lungs. You may check in a mirror that the aerosol liquid, which looks like a mist, does not leak out through the mouth or the container.

**Cleaning**

Clean the plastic parts regularly (weekly). Remove the aerosol container. Wash the plastic parts in warm – not hot – water, with addition of a mild detergent if necessary. Allow the plastic parts to dry completely and then replace the aerosol container.

**Contents under pressure**

Do not puncture or throw the container into an incinerator. Using or storing near an open flame or heating above 40°C may cause the container to burst.